Roman Belle

Dr. Roman Belle

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
IBIpek Bulut
Ipek Bulut
ALAdam Lee
Adam Lee
BCBuse Cevatemre
Buse Cevatemre
Dusan RuzicDusan Ruzic
Dusan Ruzic
RBRoman Belle
Roman Belle
CACeyda Acilan
Ceyda Acilan
Defects in epigenetic pathways are key drivers of oncogenic cell proliferation. We developed a LSD1/HDAC6 multitargeting inhibitor (iDual), a hydroxamic acid analogue of the clinical candidate LSD1 inhibitor GSK2879552. iDual inhibits both targets with IC50 values of 540, 110, and 290 nM, respectively, against LSD1, HDAC6, and HDAC8. We compared its activity to structurally similar control probes that act by HDAC or LSD1 inhibition alone, as well as an inactive null compound. iDual inhibited the growth of leukemia cell lines at a higher level than GSK2879552 with micromolar IC50 values. Dual engagement with LSD1 and HDAC6 was supported by dose dependent increases in substrate levels, biomarkers, and cellular thermal shift assay. Both histone methylation and acetylation of tubulin were increased, while acetylated histone levels were only mildly affected, indicating selectivity for HDAC6. Downstream gene expression (CD11b, CD86, p21) was also elevated in response to iDual treatment. Remarkably, iDual synergized with doxorubicin, triggering significant levels of apoptosis with a sublethal concentration of the drug. While mechanistic studies did not reveal changes in DNA repair or drug efflux pathways, the expression of AGPAT9, ALOX5, BTG1, HIPK2, IFI44L, and LRP1, previously implicated in doxorubicin sensitivity, was significantly elevated.

2 July 2018 in Chemical Communications
Verified
Journal Article
Open access
PDF file
RHRichard J. Hopkinson
Richard J. Hopkinson
GLGareth W. Langley
Gareth W. Langley
RBRoman Belle
Roman Belle
LWLouise J. Walport
Louise J. Walport
KDKate Dunne
Kate Dunne
CSChristopher J. Schofield
Christopher J. Schofield
Jumonji domain-containing demethylases (JmjC-KDMs) catalyse demethylation of Nε-methylated lysines on histones and play important roles in gene regulation. We report selectivity studies on KDM6B (JMJD3), a disease-relevant JmjC-KDM, using synthetic lysine analogues. The results unexpectedly reveal that KDM6B accepts multiple Nε-alkylated lysine analogues, forming alcohol, aldehyde and carboxylic acid products.

7 March 2022 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
RBRoman Belle
Roman Belle
JKJos J. A. G. Kamps
Jos J. A. G. Kamps
Jordi PoaterJordi Poater
Jordi Poater
KKKiran Kumar
Kiran Kumar
BPBas J. G. E. Pieters
Bas J. G. E. Pieters
Jasmin MecinovićJasmin Mecinović
Jasmin Mecinović
Nε-Methylation of lysine residues in histones plays an essential role in the regulation of eukaryotic transcription. The ‘highest’ methylation mark, Nε-trimethyllysine, is specifically recognised by Nε-trimethyllysine binding ‘reader’ domains, and undergoes demethylation, as catalysed by 2-oxoglutarate dependent JmjC oxygenases. We report studies on the recognition of the closest positively charged Nε-trimethyllysine analogue, i.e. its trimethylphosphonium derivative (KPme3), by Nε-trimethyllysine histone binding proteins and Nε-trimethyllysine demethylases. Calorimetric and computational studies with histone binding proteins reveal that H3KP4me3 binds more tightly than the natural H3K4me3 substrate, though the relative differences in binding affinity vary. Studies with JmjC demethylases show that some, but not all, of them can accept the phosphonium analogue of their natural substrates and that the methylation state selectivity can be changed by substitution of nitrogen for phosphorus. The combined results reveal that very subtle changes, e.g. substitution of nitrogen for phosphorus, can substantially affect interactions between ligand and reader domains / demethylases, knowledge that we hope will inspire the development of highly selective small molecules modulating their activity.

20 December 2024 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
KŠKlemensas Šimelis
Klemensas Šimelis
RBRoman Belle
Roman Belle
AKAkane Kawamura
Akane Kawamura
Fe(II)- and 2-oxoglutarate (2OG)-dependent dioxygenases use 2OG and O2 cofactors to catalyse substrate oxidation and yield oxidised product, succinate, and CO2. Simultaneous detection of substrate and cofactors is difficult, contributing to a poor understanding of the dynamics between substrate oxidation and 2OG decarboxylation activities. Here, we profile 5-methylcytosine (5mC)-oxidising Ten-Eleven Translocation (TET) enzymes using MS and 1H NMR spectroscopy methods and reveal a high degree of substrate oxidation-independent 2OG turnover under a range of conditions. 2OG decarboxylase activity is substantial (>20% 2OG turned over after 1 h) in the absence of substrate, while, under substrate-saturating conditions, half of total 2OG consumption is uncoupled from substrate oxidation. 2OG kinetics are affected by substrate and non-substrate DNA oligomers, and the sequence-agnostic effects are observed in amoeboflagellate Naegleria gruberi NgTet1 and human TET2. TET inhibitors also alter uncoupled 2OG kinetics, highlighting the potential effect of 2OG dioxygenase inhibitors on the intracellular balance of 2OG/succinate.

20 May 2026 in ChemMedChem
Verified
Journal Article
Open access
AFAlessandra Feoli
Alessandra Feoli
ABAmodio Luca Balzano
Amodio Luca Balzano
IPIda Pacilio
Ida Pacilio
ACAlessandra Cipriano
Alessandra Cipriano
RBRoman Belle
Roman Belle
GGianluca Sbardella
Gianluca Sbardella
Lysine demethylases of the KDM4 subfamily are epigenetic regulators frequently dysregulated in cancer, yet the identification of cell‐active inhibitors remains challenging due to assay interference and limited chemotype diversity. Here, we report the discovery of 2‐substituted‐3‐hydroxy‐2,3‐dihydroquinazolin‐4(1 H )‐ones as a new class of KDM4A inhibitors. A focused library was identified through a screening cascade integrating biochemical, biophysical, and mass spectrometry–based assays to minimize false positives. Orthogonal validation using surface plasmon resonance, nanodifferential scanning fluorimetry, and MALDI‐TOF‐MS enabled reliable compound prioritization, leading to the identification of compound 6i as a validated KDM4A binder and inhibitor. Cellular target engagement was demonstrated by quantitative label‐free proteomics, revealing a dose‐dependent accumulation of H3K9me2 and H3K9me3 in HEK293T cells, consistent with on‐target inhibition of KDM4‐family demethylases. Compound 6i further exhibited favorable solubility, permeability, and metabolic stability, supporting its qualification as a promising cell‐active KDM4 inhibitor scaffold.